TABLE 1.
Baseline characteristics of the two treatment groups
|
Triple therapy
|
||
|---|---|---|
| Seven days (n=148) | 14 days (n=166) | |
| Age, years | ||
| Mean ± SD | 60±14 | 61±13 |
| Range | 25–88 | 17–87 |
| Female sex | 95 (64, 56–72) | 87 (52, 45–60) |
| Race* | ||
| Caucasian | 135 (91, 85–95) | 146 (88, 82–92) |
| Black | 9 (6, 3–11) | 8 (5, 2–9) |
| Asian | 4 (3, 1–7) | 10 (6, 3–11) |
| Country of birth | ||
| Western Europe | 77 (52, 44–60) | 87 (52, 45–60) |
| Canada and USA | 36 (24, 18–32) | 38 (23, 17–30) |
| Central and South America | 11 (7, 4–13) | 9 (5, 3–10) |
| Eastern Europe | 9 (6, 3–11) | 5 (3, 1–7) |
| Africa | 6 (4, 2–9) | 8 (5, 2–9) |
| Asia | 3 (2, 0–6) | 10 (6, 3–11) |
| Middle East | 5 (3, 1–8) | 5 (3, 1–7) |
| Treatment setting | ||
| University hospital office | 89 (60, 52–68) | 93 (56, 48–64) |
| Community office | 59 (40, 32–48) | 73 (44, 36–52) |
| Indication | ||
| Dyspepsia | ||
| Nonulcer dyspepsia | 46 (31, 24–39) | 44 (27, 20–34) |
| Uninvestigasted dyspepsia | 4 (4, 1–7) | 3 (2, 0–5) |
| Peptic ulcer disease | ||
| Duodenal ulcer | 12 (8, 4–14) | 21(13, 8–19) |
| Gastric ulcer | 8 (5, 2–10) | 11 (7, 3–12) |
| Gastric or duodenal erosions | 4 (3, 1–7) | 6 (4, 1–8) |
| Gastroesophageal reflux disease | 26 (18, 12–25) | 34 (20, 15–27) |
| Anemia (eg, iron deficiency) | 28 (19, 13–26) | 28 (17, 11–23) |
| Family history of gastric cancer | 14 (9, 5–15) | 9 (5, 3–10) |
| Gastric cancer | 3 (2, 0–6) | 2 (1, 0–4) |
| Other† | 3 (2, 0–6) | 8 (5, 2–9) |
| Use of yogurt during treatment* | 27 (18, 12–25) | 33 (20, 14–27) |
| Confirmatory examination planned* | ||
| C-13 Urea breath test | 100 (68, 59–75) | 112 (67, 60–74) |
| C-14 Urea breath test | 36 (24, 18–32) | 41 (25, 18–32) |
| Gastroscopy and biopsy | 11 (7, 4–13) | 11 (7, 3–12) |
Data presented as n (%, 95% CI) unless otherwise indicated. P values were all nonsignificant between the two groups (ie, P>0.1) except for sex (P=0.04).
*
Some subject data were missing;
†
Other includes gastrointestinal stromal tumour, mucosa associated lymphoid tissue lymphoma, antral nodule, etc